<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00028431</url>
  </required_header>
  <id_info>
    <org_study_id>FD-R-1975-01</org_study_id>
    <secondary_id>10M-00-4;</secondary_id>
    <secondary_id>FD-R-001975-01</secondary_id>
    <nct_id>NCT00028431</nct_id>
  </id_info>
  <brief_title>Novel Adjuvants for Peptide-Based Melanoma Vaccines</brief_title>
  <official_title>An Open Label Study of MDX-CTLA4 in Combination With Tyrosinase/gp100/MART-1 Peptides Emulsified With Montanide ISA 51 in the Treatment of Patients With Resected Stage III or IV Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Southern California</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Southern California</source>
  <brief_summary>
    <textblock>
      This is a study to determine the efficacy of a melanoma vaccine chemotherapy cocktail&#xD;
      composed of CTLA-4 antibody; tyrosinase, gp100, and MART-1 peptides; and incomplete Freund's&#xD;
      adjuvant (IFA) with or without interleukin-12 in patients with resected stage III or IV&#xD;
      melanoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the Phase I/II trial, patients with resected stages III and IV melanoma who have been&#xD;
      rendered free of disease, but are at high risk of relapse, are treated with peptides/IFA at a&#xD;
      dose of 0.5 mg each peptide plus CTLA-4 antibody given intravenously, 3 mg/kg, after each&#xD;
      vaccination. In the Phase II randomized study, patients are treated with the melanoma peptide&#xD;
      vaccine alone, with CTLA-4 antibody, or with CTLA-4 antibody combined with IL-12 at 30 ng/kg&#xD;
      with alum. The peptides are tyrosinase 368-376 (370D); gp100 209-217 (210M); and MART-1 26-35&#xD;
      (27L) which are emulsified with IFA. The dosing schedule for both trials are at 1, 2, 3, 4,&#xD;
      5, and 6 months; then at 9 and 12 for a total of 8 vaccinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2001</start_date>
  <completion_date type="Actual">June 2005</completion_date>
  <primary_completion_date type="Actual">January 2003</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">19</enrollment>
  <condition>Melanoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Diagnosis of stage III or IV cutaneous, mucosal, or ocular melanoma&#xD;
&#xD;
          -  Completely resected disease or disease-free&#xD;
&#xD;
          -  HLA-A2.1 positive&#xD;
&#xD;
          -  Tumor tissue available for immunohistochemical analysis and staining positive for at&#xD;
             least 1 of the specified antigens&#xD;
&#xD;
          -  At least 1 month since prior therapy for cancer, including radiotherapy and adjuvant&#xD;
             therapy&#xD;
&#xD;
          -  WBC count at least 3,000/mm3&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 gm/dL&#xD;
&#xD;
          -  Creatinine no greater than 2.0 mg/dL&#xD;
&#xD;
          -  Bilirubin no greater than 2.0 mg/dL&#xD;
&#xD;
          -  SGOT/SGPT no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Have failed alpha-interferons (patients with resected stage III disease)&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior treatment with tyrosinase: 368-376(370D), gp100:209-217(210M), and&#xD;
             MART-1:26-35(27L) peptides&#xD;
&#xD;
          -  Steroid therapy or other immunosuppressive medication requirement&#xD;
&#xD;
          -  Major systemic infections (e.g., pneumonia or sepsis)&#xD;
&#xD;
          -  Coagulation or bleeding disorders&#xD;
&#xD;
          -  Major medical illnesses of the gastrointestinal, cardiovascular, or respiratory&#xD;
             systems&#xD;
&#xD;
          -  Allergic reaction to Montanide ISA 51 (incomplete Freund's adjuvant)&#xD;
&#xD;
          -  History of uveitis or autoimmune inflammatory eye disease&#xD;
&#xD;
          -  Other active autoimmune disease&#xD;
&#xD;
          -  Positive for hepatitis B surface antigen, hepatitis C antibody, or HIV antibody&#xD;
&#xD;
          -  Pregnant or nursing&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey S. Weber, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Southern California/Norris Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universtiy of Southern California/Kenneth Norris, Jr. Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90089</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <study_first_submitted>January 4, 2002</study_first_submitted>
  <study_first_submitted_qc>January 8, 2002</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2002</study_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stage III melanoma</keyword>
  <keyword>Stage IV melanoma</keyword>
  <keyword>Interleukin-12</keyword>
  <keyword>Cancer Vaccines</keyword>
  <keyword>Antineoplastic Agents, Combined</keyword>
  <keyword>Incomplete Freund's adjuvant</keyword>
  <keyword>Monophenol Monooxygenase</keyword>
  <keyword>Mannitol</keyword>
  <keyword>Adjuvants, Immunologic</keyword>
  <keyword>Melan-A Protein</keyword>
  <keyword>Antigens, Neoplasm</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Melanocyte lineage-specific antigen gp100</keyword>
  <keyword>CTLA-4</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ipilimumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

